SUPN

#1830
Supernus Pharmaceuticals, Inc. - Common Stock
43.9 1 USD
0.00%
Market Price
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
43.91
45.05
Rango anual
42.45
59.68
Cambio diario
+0.39%
Variación mensual
-12.96%
Variación en los últimos 6 meses
-19.09%
Cambio anual
-18.69%
Cierres anteriores
43.7 4
Open
45.0 5
Mínimo
43.9 1
Máximo
45.0 5
Volumen
85
Ver el calendario completo

Financials

Visión general Informes Estadísticas Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 13 June 2017

Full document

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by Supernus Pharmaceuticals, Inc. on June 13, 2017. The filing details the voting results for four proposals submitted to security holders. As of April 13, 2017, there were 50,228,397 shares of common stock outstanding and entitled to vote.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.

Material Changes and Voting Results

The following proposals were voted upon at the Annual Meeting:

  • Proposal 1 (Election of Class II Directors): Both nominees, Charles W. Newhall, III and Frederick M. Hudson, were elected. Significant broker non-votes (4,912,749) were recorded for this proposal.
  • Proposal 2 (Ratification of Auditors): The appointment of KPMG LLP as the independent public accounting firm for the fiscal year ending December 31, 2017, was ratified with 45,476,952 votes for and 418,886 votes against.
  • Proposal 3 (Executive Compensation): The non-binding advisory vote on executive compensation was approved with 40,375,490 votes for and 609,230 votes against.
  • Proposal 4 (Frequency of Compensation Votes): Stockholders voted to hold future advisory votes on executive compensation annually (1 Year), receiving 33,923,876 votes, compared to 6,482,629 votes for a 3-year frequency.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the results of the shareholder vote.

Important Facts for Investors

  • Shareholders approved the election of the Class II directors and the ratification of KPMG LLP as auditors.
  • Executive compensation was approved by a significant margin in the non-binding advisory vote.
  • Shareholders selected an annual frequency for future executive compensation advisory votes.
  • Broker non-votes were substantial for the director election and executive compensation proposals, totaling 4,912,749 shares in each case.

Noticias